Amilomotide

Drug Profile

Amilomotide

Alternative Names: Alzheimer's disease virus-like particle-based vaccine - Novartis; Alzheimer's disease VLP-based vaccine - Novartis; Beta-amyloid protein immunotherapy - Novartis; CAD 106; Immunodrug™ for Alzheimer's disease - Novartis

Latest Information Update: 04 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Cytos Biotechnology
  • Developer Cytos Biotechnology; Novartis
  • Class Alzheimer vaccines; Antidementias; Neuroprotectants; Virus-like particle vaccines
  • Mechanism of Action Amyloid beta-protein inhibitors; Immunomodulators; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II/III Alzheimer's disease
  • Discontinued Hypersensitivity; Rheumatoid arthritis

Most Recent Events

  • 15 Feb 2017 Discontinued - Phase-II for Alzheimer's disease in European Union, USA, Switzerland (SC)
  • 13 Jun 2016 Phase-II/III clinical trials in Alzheimer's disease in Belgium and Finland (IM) (EudraCT2015-002715-15)
  • 22 Dec 2015 Phase-II/III clinical trials in Alzheimer's disease in USA (IM) (NCT02565511)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top